Latest Eisai Co. Ltd. Stories
WOODCLIFF LAKE, N.J., July 8 /PRNewswire/ -- Eisai Corporation of North America today announced that the U.S.
TOKYO and WOODCLIFF LAKE, N.J., July 2 /PRNewswire/ -- Eisai Co., Ltd.
EXTON, Penn., July 1 /PRNewswire/ -- Morphotek(R), Inc., a subsidiary of Eisai Corporation of North America, announced a research collaboration agreement with Synageva BioPharma Corporation to express and develop therapeutic monoclonal antibodies for the potential treatment of various forms of cancer and infectious disease. Under the terms of the agreement, Synageva will use its proprietary Synageva Expression Platform (SEP(TM)) technology and its expertise to produce and develop a...
Antibody Targets Endosialin, a Protein Widely Expressed on Tumors and Tumor Blood Vessel Cells EXTON, Pa., June 9 /PRNewswire/ -- Morphotek(R), Inc., a subsidiary of Eisai Corporation of North America, announced that the U.S.
Agreement Underscores Morphotek's Commitment to the Development of Farletuzumab for Ovarian Cancer Agreement Highlights Lonza's Ability to Offer Specialty Development and Manufacturing Solutions EXTON, Pa.
Research presented to the 2009 Congressional Black Caucus Spring Health Braintrust finds African American and Hispanic adults are misinformed about Alzheimer's but support a screening test WOODCLIFF LAKE, N.J., May 4 /PRNewswire/ -- African American and Hispanic adults are more concerned about Alzheimer's disease, but are less informed about prevention of and risk factors than Caucasians, according to new survey results announced today by Eisai, Inc.
ROCKVILLE, Md. and EXTON, Pa., March 25 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc.
EXTON, Pa., March 23 /PRNewswire/ -- Morphotek(R), Inc., a subsidiary of Eisai Corporation of North America, announced today that the U.S.
SAN JOSE, Calif., March 9 /PRNewswire/ -- Teikoku Pharma USA Inc., the international specialty pharmaceutical company, announces that it has signed an exclusive worldwide (excluding Japan) licensing agreement with Eisai Co., Ltd.
EXTON, Pa., March 2 /PRNewswire/ -- Morphotek(R), Inc., a subsidiary of Eisai Corporation of North America, today announced that it has commenced a multi-centered Phase II study of its MORAb-009 monoclonal antibody in mesothelioma.
- Of or relating to good digestion.